All Oncology News

Bintrafusp alfa elicited responses in patients with recurrent/metastatic cervical cancer, warranting further exploration of TGF-β-targeted therapies.

The FDA has accepted the resubmission of a BLA for cosibelimab in advanced or metastatic cutaneous squamous cell carcinoma.

Time-limited acalabrutinib plus obinutuzumab produced responses in treatment-naive chronic lymphocytic leukemia.

Lajos Pusztai, MD, DPhil, discusses molecular residual disease monitoring in early-stage breast cancer.

Blinatumomab added to consolidation chemotherapy led to a significant OS benefit in MRD-negative B-cell precursor acute lymphoblastic leukemia.

Paolo Tarantino, MD, discusses questions about the optimal sequencing of antibody-drug conjugates in endocrine-refractory, HR-positive breast cancer.

Shubham Pant, MD, MBBS, discusses findings from the phase 2b HERIZON-BTC-01 study of zanidatamab in pretreated HER2-positive biliary tract cancer.

Eileen M. O'Reilly, MD, details how RAS-directed therapy could potentially change the pancreatic cancer landscape and highlights updated data in the space.

The FDA has accepted the new drug application for the new TLX007-CDx cold kit for the preparation of PSMA-PET imaging in patients with prostate cancer.

New START early-phase clinical trial site brings advanced cancer research to Northwell’s Cancer Institute, increases patient access

The incidence of ICANS and CRS post-CAR T-cell therapy decreased after 2 weeks in patients with DLBCL, supporting a reduction of the monitoring period.

An EHR-based prompt or “nudge” decreased the rates of sentinel lymph node biopsy among older patients with early-stage breast cancer.

Adrienne G. Waks, MD, details her approach to treatment sequencing in metastatic HER2-positive disease and the potential role of T-DXd in the first line.

Crofelemer did not improve the incidence of diarrhea in patients with solid tumors receiving targeted therapy.

Rituximab maintenance therapy following frontline bendamustine plus rituximab improved EFS, EFS2, and OS vs no maintenance therapy in patients with MCL.

Women with severe endometriosis are 10 times more likely to get ovarian cancer, compared to women who do not have the disease.

Iopofosine I 131 generated a major response rate of 56.4% in patients with relapsed/refractory Waldenström macroglobulinemia.

The FDA has accepted the resubmission of a BLA for remestemcel-L in pediatric steroid-refractory acute graft-vs-host-disease.

The ROR2-targeted ADC ozuriftamab vedotin has received FDA fast track designation in recurrent or metastatic head and neck squamous cell carcinoma.

Vishal Patel, MD, FAAD, FACMS, highlights the evolving role of PD-1 inhibitors in the management of nonmelanoma skin cancers.

Paolo Tarantino MD, and V. K. Gadi, MD, PhD discuss data from DESTINY-Breast03 and DESTINY-Breast06.

Adrienne G. Waks, MD, parses out recent and upcoming data in HER2+ breast cancer and discusses why abbreviated neoadjuvant regimens are not ready for primetime.

Sonya Reid, MD, MPH, discusses barriers to universal germline testing utilization in breast cancer, particularly among underserved populations.

Sarah Sammons, MD, discusses the evolving treatment landscape for metastatic HER2-postive breast cancer.

Circulating tumor DNA is in constant flux, rendering its evaluation potentially useful in metastatic breast cancer management.

V. Craig Jordan, PhD, of The University of Texas MD Anderson Cancer Center and a pioneer in the field of breast cancer, died on June 9, 2024.

Justin M. Watts, MD, discusses 5-year efficacy and safety data for olutasidenib in IDH1-mutant, relapsed/refractory AML.

Pembrolizumab plus ibrutinib or idelalisib produced responses in patients with Richter transformation of chronic lymphocytic leukemia.

The FDA has granted fast track designation to HP518 for androgen receptor–positive triple-negative breast cancer.

The FDA has expanded the orphan drug designation for SurVaxM, a brain cancer immunotherapy developed at Roswell Park Comprehensive Cancer Center.